La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Syros Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Syros Pharmaceuticals' est Conley Chee, nommé en Dec2023, a un mandat de moins d'un an. La rémunération annuelle totale est $ 1.04M, composée du salaire de 46% et des bonus 54%, y compris les actions et options de la société. détient directement 0.084% des actions de la société, d'une valeur de $ 34.21K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.3 ans et 11.3 ans.

Informations clés

Conley Chee

Directeur général

US$1.0m

Rémunération totale

Pourcentage du salaire du PDG	46.0%
Durée du mandat du directeur général	less than a year
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	11.3yrs

Mises à jour récentes de la gestion

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08

Analyse de la rémunération des PDG

Comment la rémunération de Conley Chee a-t-elle évolué par rapport aux bénéfices de Syros Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

Rémunération vs marché: La rémunération totale de Conley ($USD 1.04M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Conley avec les performances de l'entreprise.

PDG

Conley Chee (54 yo)

less than a year

Titularisation

US$1,041,697

Compensation

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.084% $ 39.2k
Richard Young	Scientific Founder	no data	US$82.15k	0.030% $ 13.9k
Jason Haas	Chief Financial Officer	2.8yrs	US$833.02k	0.092% $ 42.7k
David Roth	Chief Medical Officer	8.7yrs	US$876.53k	0% $ 0
James Bradner	Founder	no data	pas de données	pas de données
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	pas de données	pas de données
Karen Hunady	Director of Corporate Communications & Investor Relations	no data	pas de données	pas de données
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	1.8yrs	US$1.46m	0.15% $ 69.2k
Lisa Roberts	Vice President of Human Resources	1.6yrs	pas de données	pas de données
Kristin Stephens	Chief Development Officer	4.2yrs	pas de données	0.094% $ 43.9k

2.3yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Gestion expérimentée: L'équipe de direction de SYRS est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.084% $ 39.2k
Richard Young	Scientific Founder	12.8yrs	US$82.15k	0.030% $ 13.9k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données
Peter Karl Wirth	Independent Chairman	7.6yrs	US$110.40k	0.060% $ 27.8k
Mark Murcko	Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données
Andrew Oh	Independent Director	1.9yrs	US$78.53k	0.060% $ 27.8k
Nancy Simonian	Director	11.3yrs	US$1.49m	0.51% $ 236.0k
Gerard Evan	Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données
Scott Biller	Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données
Bradley Bernstein	Member of Scientific Advisory Board	no data	pas de données	pas de données
Stefan Knapp	Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données
Aviv Regev	Member of Scientific Advisory Board	11.3yrs	pas de données	pas de données

11.3yrs

Durée moyenne de l'emploi

63.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration SYRS sont chevronnés et expérimentés (durée moyenne d'administration 11.3 ans).

Syros Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Scientific Founder notifies of intention to sell stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Director exercised options and sold US$72k worth of stock

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insider recently bought US$106k worth of stock

Recent updates

Price target decreased by 56% to US$8.75

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

New major risk - Financial position

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Scientific Founder notifies of intention to sell stock

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Director exercised options and sold US$72k worth of stock

Consensus revenue estimates decrease by 59%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Forecast to breakeven in 2026

Price target decreased by 12% to US$20.00

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

New major risk - Share price stability

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Price target decreased by 16% to US$21.25

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Price target decreased by 16% to US$21.25

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 10% to US$26.50

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Price target decreased to US$25.40

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Consensus revenue estimates fall by 11%

Insufficient new directors

Consensus forecasts updated

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought US$106k worth of stock

Consensus forecasts updated

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Q2 2022 Earnings Preview

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

Consensus forecasts updated

Consensus estimates of losses per share improve by 11%

Price target decreased to US$14.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Syros Pharmaceuticals Is A Buy As New Trials Start